ReviewClinical reviews in allergy & immunology2012
Immunological orchestration of liver fibrosis.
Review in Clinical reviews in allergy & immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Immunological factors in cirrhosis diseases from a bibliometric point of view.World journal of gastroenterology · 2023Review
- Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma.Cancer prevention research (Philadelphia, Pa.) · 2020Article
- Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice.Frontiers in immunology · 2018Article
- Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and Implications for Autoimmunity.Clinical reviews in allergy & immunology · 2016Review
- Inhibitory effect of liposomal quercetin on acute hepatitis and hepatic fibrosis induced by concanavalin A.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2014Article
- Hepatic inflammation and progressive liver fibrosis in chronic liver disease.World journal of gastroenterology · 2014Review
- Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis.Clinical and experimental immunology · 2013Article
- Regulation of the cytosolic sulfotransferases by nuclear receptors.Drug metabolism reviews · 2013Review
- The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias.Clinical reviews in allergy & immunology · 2012Review
- Circulating levels of a collagen type v propeptide fragment in a carbon tetrachloride reversible model of liver fibrosis.Biomarker insights · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosis represents the main pathophysiological consequence of all chronic inflammatory liver diseases and ultimately leads to the life-threatening clinical consequences of cirrhosis. Regardless of the underlying etiology, fibrosis involves interplay between cells of the immune systems and the direct mediators of fibrosis, including hepatic stellate cells. However, the precise physiological mechanism of liver fibrosis remains largely on enigma. Primary biliary cirrhosis (PBC) is a unique chronic, fibrosing liver disease affecting predominantly women and characterized by an immune-mediated specific destruction of the small intrahepatic bile ducts. The presence of highly specific anti-mitochondrial autoantibodies (AMA) as well as T cell responses directed agonist the pyruvate dehydrogenase E2 complex (PDC-E2) provides a unique opportunity to assess the interaction between specific immune responses and fibrogenesis. In addition, mouse models of PBC have been developed allowing the dissection of mechanisms involved in breakdown of immune tolerance, bile duct injury, and fibrosis. Recently, we reported that liver fibrosis could be induced in a xenobiotic-induced murine model of PBC by polyinosinic-polycytidylic acid (poly I:C) treatment as well as with the administration of α-galactosylceramide (α-GalCer). The aim of this article is to provide a current perspective of the immunological mechanisms that are significant in the fibrogenic processes, and potentially, for its regression by comparing PBC with other chronic inflammatory liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.